Effect and mechanism of Bovis Calculus on ulcerative colitis by inhibiting IL-17/IL-17RA/Act1 signaling pathway.
10.19540/j.cnki.cjcmm.20230117.704
- Author:
Jian-Mei YUAN
1
;
Dan-Ni LU
1
;
Jia-Jun WANG
1
;
Zhuo XU
1
;
Yong LI
1
;
Mi-Hong REN
1
;
Jin-Xiu LI
1
;
Dao-Yin GONG
2
;
Jian WANG
1
Author Information
1. School of Pharmacy, Chengdu University of Traditional Chinese Medicine Chengdu 611137, China Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China,Chengdu University of Traditional Chinese Medicine Chengdu 611137, China.
2. Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China.
- Publication Type:Journal Article
- Keywords:
Bovis Calculus;
IL-17;
UC model mice;
network pharmacology;
ulcerative colitis
- MeSH:
Mice;
Animals;
Colitis, Ulcerative/metabolism*;
Tumor Necrosis Factor-alpha/metabolism*;
Interleukin-6/metabolism*;
Interleukin-17/pharmacology*;
TNF Receptor-Associated Factor 2/pharmacology*;
TNF Receptor-Associated Factor 5/metabolism*;
Mice, Inbred C57BL;
Signal Transduction;
Colon;
p38 Mitogen-Activated Protein Kinases/metabolism*;
RNA, Messenger/metabolism*;
Dextran Sulfate/metabolism*;
Disease Models, Animal
- From:
China Journal of Chinese Materia Medica
2023;48(9):2500-2511
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to elucidate the effect and underlying mechanism of Bovis Calculus in the treatment of ulcerative colitis(UC) through network pharmacological prediction and animal experimental verification. Databases such as BATMAN-TCM were used to mine the potential targets of Bovis Calculus against UC, and the pathway enrichment analysis was conducted. Seventy healthy C57BL/6J mice were randomly divided into a blank group, a model group, a solvent model(2% polysorbate 80) group, a salazosulfapyridine(SASP, 0.40 g·kg~(-1)) group, and high-, medium-, and low-dose Bovis Calculus Sativus(BCS, 0.20, 0.10, and 0.05 g·kg~(-1)) groups according to the body weight. The UC model was established in mice by drinking 3% dextran sulfate sodium(DSS) solution for 7 days. The mice in the groups with drug intervention received corresponding drugs for 3 days before modeling by gavage, and continued to take drugs for 7 days while modeling(continuous administration for 10 days). During the experiment, the body weight of mice was observed, and the disease activity index(DAI) score was recorded. After 7 days of modeling, the colon length was mea-sured, and the pathological changes in colon tissues were observed by hematoxylin-eosin(HE) staining. The levels of tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β), interleukin-6(IL-6), and interleukin-17(IL-17) in colon tissues of mice were detected by enzyme-linked immunosorbent assay(ELISA). The mRNA expression of IL-17, IL-17RA, Act1, TRAF2, TRAF5, TNF-α, IL-6, IL-1β, CXCL1, CXCL2, and CXCL10 was evaluated by real-time polymerase chain reaction(RT-PCR). The protein expression of IL-17, IL-17RA, Act1, p-p38 MAPK, and p-ERK1/2 was investigated by Western blot. The results of network pharmacological prediction showed that Bovis Calculus might play a therapeutic role through the IL-17 signaling pathway and the TNF signaling pathway. As revealed by the results of animal experiments, on the 10th day of drug administration, compared with the solvent model group, all the BCS groups showed significantly increased body weight, decreased DAI score, increased colon length, improved pathological damage of colon mucosa, and significantly inhibited expression of TNF-α,IL-6,IL-1β, and IL-17 in colon tissues. The high-dose BCS(0.20 g·kg~(-1)) could significantly reduce the mRNA expression levels of IL-17, Act1, TRAF2, TRAF5, TNF-α, IL-6, IL-1β, CXCL1, and CXCL2 in colon tissues of UC model mice, tend to down-regulate mRNA expression levels of IL-17RA and CXCL10, significantly inhibit the protein expression of IL-17RA,Act1,and p-ERK1/2, and tend to decrease the protein expression of IL-17 and p-p38 MAPK. This study, for the first time from the whole-organ-tissue-molecular level, reveals that BCS may reduce the expression of pro-inflammatory cytokines and chemokines by inhibiting the IL-17/IL-17RA/Act1 signaling pathway, thereby improving the inflammatory injury of colon tissues in DSS-induced UC mice and exerting the effect of clearing heat and removing toxins.
